No spam. Unsubscribe anytime.
Incretin Pathway Comparator Kit
Single vs. dual receptor activation — the compounds from the STEP and SURPASS trials
Pairs the two leading GLP-1 pathway agonists studied in major published trials. Semaglutide provides pure GLP-1 receptor activation (the mechanism examined in the STEP trials), while Tirzepatide adds dual GIP/GLP-1 engagement (studied in the SURPASS trials). Having both enables direct mechanistic comparison of single vs. dual-receptor approaches as described in peer-reviewed literature.
$37.78/vial avg · 8 vials total · Everything you need
Research Protocol Timeline
Week-by-week observations documented in published peer-reviewed studies
Receptor Engagement & Titration Initiation
- Published STEP trial data documented initial GLP-1 receptor engagement with appetite modulation observed in the majority of study participants within 7-14 days
- In peer-reviewed studies, low-dose titration of Semaglutide (0.25 mg/week) demonstrated early satiety signaling changes without significant GI disturbance in most subjects
- Literature demonstrates Tirzepatide's dual GIP/GLP-1 engagement producing complementary incretin effects from the first administered dose in SURPASS trial cohorts
- Study participants reported changes in hunger-signaling patterns, particularly reduced between-meal appetite, as documented in published trial observations
Dose Escalation & Metabolic Adaptation
- Published research observed dose-dependent increases in insulin sensitivity markers following standard titration protocols in both STEP and SURPASS studies
- In peer-reviewed studies, GLP-1 receptor activation demonstrated hepatic glucose output modulation, with measurable fasting glucose changes in study cohorts
- Literature demonstrates Tirzepatide's GIP receptor co-activation producing enhanced beta-cell responsiveness compared to GLP-1-only approaches in published head-to-head data
- Study participants reported consistent reduction in caloric intake markers, with published food-diary data showing 20-30% decreases in ad libitum consumption
Active Metabolic Response Phase
- Published STEP 1 trial data documented mean body weight reductions of 5-7% by week 8 in the Semaglutide cohort at escalated dosing
- In peer-reviewed SURPASS trials, Tirzepatide demonstrated superior glycemic control markers compared to selective GLP-1 agonists at equivalent timepoints
- Literature demonstrates measurable changes in visceral adipose tissue distribution as assessed by DEXA in published body composition substudies
- Study participants reported stabilization of GI adaptation with reduced nausea frequency as tolerance developed during dose maintenance
Cardiovascular & Lipid Marker Changes
- Published research observed significant modifications in lipid panel markers including LDL-C, triglycerides, and HDL-C in study populations by this timepoint
- In peer-reviewed SELECT trial data, Semaglutide demonstrated cardiovascular outcome benefits independent of weight-change markers in high-risk cohorts
- Literature demonstrates reductions in systolic blood pressure of 4-6 mmHg in published SURPASS trial data during this protocol phase
- Study participants showed measurable improvements in inflammatory markers including hs-CRP in published metabolic substudies
Body Composition Remodeling
- Published STEP trial data documented continued linear weight reduction with mean losses of 10-14% from baseline in the active treatment arm
- In peer-reviewed studies, Tirzepatide at highest titrated doses demonstrated up to 22.5% mean weight reduction in the SURPASS-II cohort
- Literature demonstrates preferential reduction in visceral adipose tissue with relative preservation of lean mass in published DEXA substudies
- Study participants showed measurable improvements in insulin sensitivity markers approaching normoglycemic ranges in published data
Metabolic Stabilization
- Published research observed plateau effects in body weight trajectory indicating new metabolic setpoint establishment in study cohorts
- In peer-reviewed studies, sustained GLP-1/GIP receptor activation demonstrated maintained appetite suppression without significant tachyphylaxis at stable doses
- Literature demonstrates improvements in hepatic steatosis markers including ALT normalization and liver fat content reduction in published MRI substudies
- Study participants reported sustained energy level markers and improved physical function scores as documented in published quality-of-life assessments
Protocol Endpoint Assessment
- Published STEP and SURPASS trial endpoints documented comprehensive metabolic improvements across glycemic, lipid, and body composition markers at 16 weeks
- In peer-reviewed research, comparative analysis of Semaglutide vs. Tirzepatide provided data on differential receptor-activation outcomes at equivalent timepoints
- Literature demonstrates that published trial data supports assessment of continued administration vs. dose modification based on individual response markers
- Study participants showed maintained metabolic changes, with published data indicating that response markers remain modified with sustained receptor engagement
Published Research
Peer-reviewed studies supporting this compound combination
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. — The New England Journal of Medicine, 2021
Published data demonstrated 14.9% mean body weight reduction with Semaglutide 2.4 mg weekly vs. 2.4% with placebo over 68 weeks in participants with overweight or obesity.
PMID: 33567185
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. — The New England Journal of Medicine, 2022
In peer-reviewed research, Tirzepatide at 15 mg weekly demonstrated mean weight reductions of 22.5% at 72 weeks, the largest weight reduction observed with a pharmacological agent in published trial data.
PMID: 35658024
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frias JP, Davies MJ, Rosenstock J, et al. — The New England Journal of Medicine, 2021
Published head-to-head data demonstrated Tirzepatide superiority over Semaglutide in HbA1c reduction and body weight change, with dual GIP/GLP-1 activation producing enhanced metabolic outcomes.
PMID: 34170647
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Marso SP, Bain SC, Consoli A, et al. — The New England Journal of Medicine, 2016
Literature demonstrates Semaglutide produced a 26% reduction in major adverse cardiovascular events in published trial data, establishing cardiovascular benefit beyond glycemic control.
PMID: 27633186
What Researchers Track
Common measurements and biomarkers for this protocol type
Reconstitution & Handling
Water Volume
2 mL bacteriostatic water per 10mg vial
Concentration
5 mg/mL — titrate from 0.25 mg/week according to published protocols
Storage
Refrigerate at 2-8°C after reconstitution. Stable for up to 42 days. Do not freeze.
What the Research Shows
Peer-reviewed findings on each compound and their complementary mechanisms
Semaglutide is a GLP-1 receptor agonist studied extensively in the STEP clinical trials, demonstrating significant effects on appetite regulation and metabolic markers (PMID: 33567185).
Tirzepatide is a dual GIP/GLP-1 receptor agonist. The SURPASS trials showed it acts on two incretin pathways simultaneously, with notable results in metabolic research (PMID: 35658024).
Having both compounds available allows researchers to compare single vs. dual-receptor approaches, or study sequential administration patterns.
Research Dosing Reference
Dosing ranges cited in published studies — 12-16 weeks per peptide research protocol
Semaglutide
Tirzepatide
Research Protocol Notes
These peptides are typically used one at a time, not simultaneously. Published sequencing protocols begin with Semaglutide to establish baseline, followed by Tirzepatide if a dual-agonist approach is preferred. Published protocols use gradual titration to minimize GI side effects.
What's in This Kit
2 peptides, each with individual COA documentation
Semaglutide
$46.95Clinically studied for steady weight reduction — once weekly
Semaglutide is a research peptide in the glp-1 / weight management category. Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release. MiPeptidos offers Semaglutide in 6 sizes with 99.1% verified purity and full analytical documentation.
Tirzepatide
$41.95The most studied dual-agonist for weight reduction
Tirzepatide is a research peptide in the glp-1 / weight management category. Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. MiPeptidos offers Tirzepatide in 10 sizes with 99.2% verified purity and full analytical documentation.
What Customers Say
Reviews from customers using peptides in this research kit
Frequently Asked Questions
Common questions about the Incretin Pathway Comparator Kit research kit
Related Research Kits
Triple Incretin Comparator Kit
Single, dual, and triple agonists — the three compounds studied in STEP, SURPASS, and NEJM Phase 2 trials
3 peptides · Metabolic Research
Lipolytic Pathway Study Kit
Three lipolytic mechanisms studied in published research — HGH-fragment activity plus mitochondrial oxidation
3 peptides · Metabolic Research
Tissue Repair Research Kit
The two most-cited tissue repair peptides studied together in published literature
2 peptides · Tissue Research
Start Your Research
Get the complete Incretin Pathway Comparator Kit at $80.01 — save $8.89 versus purchasing each compound separately. Full COA documentation included with every vial.
Research Use Only. These products are intended for laboratory research purposes only. Not for human consumption. Dosing information is provided for research reference only. Consult a licensed healthcare provider before beginning any peptide protocol.